Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan).
Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.
Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).
Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.
Biosimilar to Remicade
Expected U.S. launch in 2023.
Biosimilars may need more time to devleop in the market.
Biologic medicines could lower spending by $153 billion by 2023.
New changes are making it more difficult for generics and biosimilars to compete on formularies.
Blockbuster drug could be key to Humira’s successor.